Dubai: TheSocialMedwork has revealed Aimovig, the transformative migraine drug, is the most sought after medicine on their site from patients in the Middle East, with 657 people seeking information about this medicine in just 30 days from July 5th to August 5th. This is followed by Ocrevus (used to treat multiple sclerosis - 569 people), Spinraza (used to treat spinal muscular atrophy - 525 people), Venclexta (a medication used for the treatment of chronic lymphocytic leukemia - 273 people) and Radicut (used to treat amyotrophic lateral sclerosis, also known as motor neurone disease - 190 people).

TheSocialMedwork helps people access medicines approved by foreign health regulatory authorities, such as the U.S. FDA and EMA and not currently available in the Middle East. Using existing legal structures for 'named patient' imports, the medical startup, which is fully licensed and regulated by the Ministry of Health in The Netherlands, has delivered to patients across the GCC medicines for Aimovig (erenumab), Generic Edaravone and Radicut (edaravone) so far.

Aimovig (erenumab) was the most sought after medicine in Saudi Arabia, Kuwait, Bahrain, Qatar, Lebanon, and Iran. In 2018, order requests for the medicine were processed from patients in Saudi Arabia, UAE and Kuwait. Venclexta, the medicine used to treat chronic lymphocytic leukemia, was also in the top five sought after medicines from the Kingdom with 20 people expressing interest last year.

In each country mentioned, the requested drug is currently unavailable meaning patients would have to travel to another country to obtain treatment. Now, with TheSocialMedwork people can get a prescription from their treating doctor and order it online. TheSocialMedwork will help guide each person through importing it and oversees all aspects of the delivery and customs process. The organisations ensures the medicine is ready for administration by a healthcare provider and that every package arrives in perfect condition - with all specialist shipping conditions like refrigerated packaging (called cold chain shipping) being handled by the team of qualified pharmacists, logistic experts and healthcare professionals.

Aimovig (erenumab) is just one of the 60 medicines available on the platform, which has delivered almost 4,000 medicines to patients in 70 countries across the world. Sufferers of debilitating and chronic diseases can now access vital new treatments months, even years, faster and no longer need complex trips abroad to seek the latest care.

Over 20% of the TheSocialMedwork’s business is from helping people in the Middle East and demand for medicines via the platform is growing rapidly.

The Dutch healthcare startup which was founded in 2014 by Sjaak Vink, James Heywood, Bernard Muller, himself an ALS patient, and Katrin Schepp, and dispenses medicines only with a valid prescription and can deliver to the patient, a pharmacy or hospital - depending on local regulations.

For a full list of medicines available and information on how to access them, visit: https://thesocialmedwork.com/

-Ends-

For further information contact: zainab@popcomms.ae / 050 887 5879

About TheSocialMedwork

TheSocialMedwork is an online platform where patients and doctors can source a newly approved medicine that is currently unavailable to them and have it delivered to a pharmacy or hospital in their home country. Founded in 2014, TheSocialMedwork has shipped nearly 4,000 medicines to 70 countries and currently lists 60 medications on its website, adding more regularly. TheSocialMedwork strives to make new medicines available two weeks after they are approved by a reputable medical authority. Our focus is to solve the delay between first approval and global availability which can be as long as five years. Patients with severe conditions and progressive diseases cannot wait that long. TheSocialMedwork helps people access new medicines that have the potential to make a positive impact on their health, life expectancy and quality of life. The team delivers newly approved medicines around the world every day.

As a social enterprise startup the organisation is committed to its mission of making the best healthcare options accessible to everyone. The platform was founded when Sjaak Vink and Jamie Heywood — Founder and Chairman of the largest online patient community in the world Patients Like Me — both lost friends and family members to diseases due to a nonsensical reason: the inaccessibility of new medicines; a problem that could be solved. They were joined by Bernard Muller, co-founder of the world’s largest genetic data collection program Project MinE who had just been diagnosed with ALS himself, and Attorney-at-Law Katrin Schepp who’s father passed away of cancer. The organisation's first angel investor was acclaimed Silicon Valley healthcare investor-activist Esther Dyson.

https://thesocialmedwork.com

About erenumab (Aimovig)

The newly approved medicine, erenumab (trade name Aimovig) falls within a category of drugs that’s received much attention recently: inhibitors of calcitonin gene-related peptide, also known as CGRP. CGRP is thought to increase during migraine. By blocking the receptors of CGRP, erenumab is a unique preventative treatment that aims to reduce both intensity and frequency of migraines.

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.